Damora Therapeutics, Inc. (DMRA) annual cash flow statement — 8-year operating, investing & financing history
Damora Therapeutics, Inc. (DMRA) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -59.13M | -6.73M | -18.62M | -36.91M | -42.93M | -52.31M | -38.2M | -19.33M | -13.69M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 0% | 63.88% | 49.55% | 14.02% | 17.92% | -36.92% | -97.68% | -41.16% | - |
| Net Income | -291.68M | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Depreciation & Amortization | 91K | 34K | 181K | 830K | 490K | 441K | 188K | 111K | 0 |
| Stock-Based Compensation | 8.02M | 998K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 192.17M | 183.72M | 5.3M | 4.98M | 6.26M | 5.63M | 1.04M | 14.88M | 3.11M |
| Working Capital Changes | 32.27M | 18.36M | -2.67M | -4.37M | 11.94M | -6.62M | -4.59M | 2.19M | -933K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 22.77M | 17.27M | -1.32M | -1.65M | 1.82M | -1.32M | -477K | 1.94M | 733K |
| Cash from Investing | -196.13M | -17.37M | 11.65M | 22.33M | 12.38M | -48.05M | 0 | -326K | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -196K | -223K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | -17.37M | 0 | 83K | 0 | 0 | 0 | -326K | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 597.39M | 266.84M | 0 | 2.88M | 507K | 0 | 187.39M | 0 | 42.87M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.51M |
| Equity Issued (Net) | 597.39M | 266.81M | 0 | 2.88M | 507K | 0 | 187.39M | 0 | 34.36M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 342.05M | 243.45M | -7.29M | -11.32M | -29.78M | -101.02M | 152.29M | -19.69M | 30.99M |
| Free Cash Flow | -59.13M | -6.73M | -18.62M | -36.91M | -43.13M | -52.53M | -38.2M | -19.33M | -13.69M |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 63.88% | 49.55% | 14.42% | 17.9% | -37.5% | -97.68% | -41.16% | - |
| FCF per Share | -3.61 | -4.93 | -16.09 | -34.73 | -42.43 | -51.99 | -37.81 | -19.00 | -13.46 |
| FCF Conversion (FCF/Net Income) | 0.20x | 0.03x | 0.87x | 0.96x | 0.70x | 1.01x | 1.10x | 0.53x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DMRA stock.
Damora Therapeutics, Inc. (DMRA) generated $-6.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Damora Therapeutics, Inc. (DMRA) reported negative free cash flow of $6.7M in 2025, indicating capital requirements exceeded cash from operations.
Damora Therapeutics, Inc. (DMRA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.